Načítá se...
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
In recent years, immune checkpoint inhibitors have emerged as effective therapies for advanced neoplasias. As new checkpoint target blockers become available and additional tumor locations tested, their use is expected to increase within a short time. Immune-related adverse events (irAEs) affecting...
Uloženo v:
| Vydáno v: | Oncologist |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AlphaMed Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4943391/ https://ncbi.nlm.nih.gov/pubmed/27306911 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0509 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|